Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Next Previous
Trial Profile

KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Immune globulin
  • Indications Mucocutaneous lymph node syndrome
  • Focus Therapeutic Use
  • Acronyms KIDCARE

Most Recent Events

  • 21 May 2026 According to Oddifact media release, the company announced that the European Commission, following a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), has granted Orphan Drug Designation for infliximab for the treatment of Kawasaki disease. This European designation follows the Orphan Drug Designation previously granted by the FDA for the same indication. The clinical rationale for infliximab in Kawasak disease is supported by this study.
  • 21 May 2026 According to Oddifact media release, this study was published in The Lancet Child & Adolescent Health in 2021.
  • 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2019).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top